R&D News | pharmaphorum

News

J&J builds in CAR-T with $245m Cellular Biomedicine deal

Johnson & Johnson’s appetite for building a new generation of CAR-T therapies for cancer shows no sign of being sated – its Janssen Biotech unit has just paid $245 mil

News

Sanofi finds new Pompe disease therapy in Maze

Sanofi is already a big player in the Pompe disease market with injectable drugs like Nexviazyme and Myozyme/Lumizyme, but has now set its sights on an oral drug candidate

News

Astellas cuts $5.9bn deal to buy Iveric Bio

Astellas Pharma has agreed its largest-ever acquisition, buying US biotech Iveric Bio in a deal that continues to build its presence in the ophthalmology sector,

News

Lilly trumpets new weight-loss data with Mounjaro

Eli Lilly’s new therapy Mounjaro has aced a second phase 3 trial as a treatment of obesity or being overweight, this time in patients with type 2 diabetes.

News

Boerner to lead BMS after CEO Caforio steps down

Bristol-Myers Squibb’s long-serving chief executive Giovanni Caforio has said he will retire on 1st November after almost eight years in the role and more than two decades

News

Vabysmo vaults into Roche’s top growth spot

The undisputed star of Roche’s pharma portfolio in the first quarter of this year is eye disease therapy Vabysmo, heading for blockbuster territory after posting sales of

J&J builds in CAR-T with $245m Cellular Biomedicine deal

Sanofi finds new Pompe disease therapy in Maze

Astellas cuts $5.9bn deal to buy Iveric Bio

Lilly trumpets new weight-loss data with Mounjaro

Boerner to lead BMS after CEO Caforio steps down

Vabysmo vaults into Roche’s top growth spot

Lilly partners with Hims & Hers on obesity drug sales

Discover a new era of healthcare panel engagement: Grounded ...

News

Editor's Picks